By Elsa Ohlen
Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to be more efficient than its blockbuster drugs currently on the market, Ozempic and Wegovy.
U.S. traded shares in Novo Nordisk A/S were up 9.1% to $88.45 in premarket trading while Danish listed shares rose about 5%.
The mid-stage clinical trial showed patients that moved to the highest dosage of 20mg of the new medicine Amycretin lost 22% of their body weight in over 36 weeks.
Shares of Novo's main rival Eli Lilly fell 1.3%.
This is breaking news. Check back for more analysis soon.
Write to Elsa Ohlen at elsa.ohlen@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
January 24, 2025 06:05 ET (11:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。